Compugen Ltd. files foreign-issuer reports that document its clinical-stage cancer immunotherapy business, financial results and material corporate developments. Its Form 6-K filings cover quarterly and annual results, interim consolidated financial statements, management discussion and analysis, Inline XBRL financial data, and corporate updates related to programs such as COM701, COM902, rilvegostomig and GS-0321.
The filing record also documents licensing and royalty arrangements, including amendments to the AstraZeneca rilvegostomig agreement, as well as proxy materials, annual general meeting voting results, board composition and registration-statement incorporation matters under Form F-3. These disclosures frame Compugen's capital resources, collaboration economics, governance actions, clinical-development disclosures and foreign private issuer reporting obligations.
Compugen Ltd. reported a sharp turnaround in 2025, moving to net profit and strengthening its balance sheet. For the year ended December 31, 2025, revenue was approximately $72.8 million, up from about $27.9 million in 2024, driven mainly by a $65 million upfront payment from AstraZeneca and payments from a license agreement with Gilead.
The company posted net profit of approximately $35.3 million in 2025, compared with a net loss of about $14.2 million a year earlier. As of December 31, 2025, cash, cash equivalents, short-term deposits and marketable securities totaled roughly $145.6 million, and the company stated it expects this to fund operations into 2029, with no debt.
Management highlighted progress in its immuno-oncology pipeline, including new trials for COM701 in ovarian cancer (MAIA-ovarian) and Phase 1 development of GS-0321 licensed to Gilead, alongside AstraZeneca’s advancement of rilvegostomig in multiple Phase 3 cancer trials.
Compugen Ltd. filed a report describing the appointment of Michele Holcomb, Ph.D. as a new independent director to its Board, effective February 11, 2026. She will serve until immediately after the 2026 annual general meeting or until a successor is elected or her office is vacated earlier.
The company highlights Dr. Holcomb’s more than 30 years of experience across biotech, pharmaceuticals, and healthcare services, including senior roles at Cardinal Health, Teva Pharmaceuticals, and McKinsey & Company, as well as current board positions at PureTech Health, Kimball Electronics, and Controlant.
Compugen Ltd. entered into an amendment with MedImmune Limited, part of the AstraZeneca Group, under which it sold to AstraZeneca a portion of its existing royalty interest in the cancer immunotherapy candidate rilvegostomig for a $65 million upfront payment, due within five business days of the December 16, 2025 amendment date.
The amendment also increases by $25 million the milestone payment payable to Compugen upon the next milestone, defined as the first acceptance of the Biologics License Application for rilvegostomig.
This transaction shifts part of Compugen’s expected future royalty stream into near-term cash while enhancing the potential size of a key future regulatory milestone payment linked to BLA acceptance.
Compugen Ltd. (CGEN) filed a Form 6-K stating it furnished a press release with the company’s third quarter 2025 results as Exhibit 99.1. The filing notes that, with the exception of quotes attributed to Eran Ophir, Ph.D., the press release is incorporated by reference into the company’s effective Form F-3 registration statement (File No. 333-270985).
The report was signed by Eran Ben Dor, General Counsel, on November 10, 2025. Investors seeking financial details should refer to Exhibit 99.1, which contains the full Q3 2025 results.
Compugen Ltd. (CGEN) filed a Form 6-K noting it issued a press release on October 13, 2025, which is furnished as Exhibit 99.1. With the exception of the third, fourth, and fifth paragraphs of the press release, the information incorporated by reference in this report is also incorporated into the Company’s Registration Statement on Form F-3 (File No. 333-270985).
The report was signed by Eran Ben Dor, General Counsel, on October 14, 2025.
Compugen Ltd. reports that it held its 2025 Annual General Meeting of Shareholders on September 16, 2025. According to the company, all proposals presented to shareholders at the meeting were approved by the required majority, meaning each item on the agenda received sufficient support to pass. The notice of meeting, proxy statement and proxy card had previously been filed with the SEC and are incorporated by reference. The company also states that the information in this report is incorporated by reference into its existing shelf registration statement on Form F-3.